Author

Estes C

August 30, 2021
Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies
Summary Background & aims The aim of this study was to quantify the global epidemiology of primary sclerosing cholangitis (PSC), alongside the incidence of liver transplantation, cancer, and death, through robust systematic review of population-based data. Methods We searched MEDLINE and EMBASE up to and including June 30, 2020 to identify population-based studies reporting the […]

Read More
August 7, 2020
Impact of COVID-19 on global HCV elimination efforts
Summary Background & Aims Coronavirus disease 2019 (COVID-19) has placed a significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change […]

Read More
June 13, 2020
Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors’ reply
Summary No abstract available. Countries: Singapore, South Korea

Read More
June 9, 2020
Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study
Summary Background Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a growing proportion of liver disease cases, and there is a need to better understand future disease burden. We used a modelling framework to forecast the burden of disease of NAFLD and NASH for Canada. Methods We used a Markov model to […]

Read More
May 1, 2020
Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
Summary Importance Achievement of the World Health Organization (WHO) target of eliminating hepatitis C virus (HCV) by 2030 will require an increase in key services, including harm reduction, HCV screening, and HCV treatment initiatives in member countries. These data are not available for Canada but are important for informing a national HCV elimination strategy. Objective […]

Read More
March 4, 2020
Modelling NAFLD disease burden in four Asian regions-2019-2030
Summary Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia-Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations. Aims To estimate using modelling the growth in NAFLD populations, including cases with significant fibrosis that are […]

Read More
February 26, 2020
Nonalcoholic fatty liver disease burden: Australia, 2019-2030
Summary Background and Aim Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a large and growing proportion of liver disease burden globally. The burden of NAFLD/NASH manifests in increasing levels of advanced liver disease and primary liver cancer in Australia. A Markov model was used to forecast NAFLD burden in Australia through […]

Read More
January 16, 2020
Global prevalence of hepatitis C virus in children in 2018: a modelling study
Summary Background Hepatitis C virus (HCV) prevalence estimates for adults and high-risk groups have been widely published, but the disease burden in children is poorly understood. Direct-acting antiviral drugs, which are considered to be highly effective curative therapies for HCV, are now approved for paediatric patients as young as 3 years. Reliable prevalence estimates for […]

Read More
December 17, 2019
Nonalcoholic fatty liver disease burden – Switzerland 2018-2030
Summary As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland. A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term […]

Read More
November 14, 2018
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake – a modeling study
Summary Subsidized direct-acting antiviral (DAA) treatment recently became available to all adults living with chronic hepatitis C (HCV) in Australia. Based on rapid uptake (32,600 people initiated DAA in 2016) we estimated the impact on HCV epidemiology and mortality in Australia and determined if Australia can meet the WHO HCV elimination targets by 2030. Using […]

Read More